Abingdon Health plc (AIM: ABDX), a lateral flow contract research (CRO) and contract development and manufacturing organisation (CDMO), announced on Wednesday that its subsidiary, CS (Lifesciences) Ltd, has secured a contract with a global diagnostics company.

The deal, which begins in March 2025, will span 12 months, generating more than GBP500,000 in revenue. The contract focuses on quality management systems and regulatory approvals.

CS (Lifesciences) Ltd, acquired by Abingdon in August 2024, specialises in compliance for international in vitro diagnostics (IVD) and medical device markets. This acquisition strengthens Abingdon's service offerings, enabling the Group to support customers from product concept to commercialisation.

Abingdon Health's contract development and manufacturing organisation (CDMO) division provides lateral flow product development, technology transfer, manufacturing and regulatory support. This division caters to sectors including infectious diseases, clinical testing, companion diagnostics, animal health and environmental testing.

Additionally, Abingdon's regulatory services, through Compliance Solutions (Life Sciences) and IVDeology, assist clients in navigating regulatory requirements for markets such as the USA, EU and UK. Their services include quality management system implementation, technical file preparation, interim management and audits.

Abingdon Health also operates the Abingdon Simply Test range, an e-commerce platform offering self-tests to consumers. The platform provides valuable information on health tests and serves as a potential route to market for Abingdon's contract services clients.

Founded in 2008, Abingdon Health is headquartered in York, England.